Gerstein HC, Pare G, McQueen MJ, et al. - In this research, investigators distinguish novel biomarkers that can better assume changes in renal function than routinely available clinical markers. They tested concentration of 239 biochemical markers in stored serum from individuals in the biomarker substudy of Outcomes Reduction with an Initial Glargine Intervention trial. They further applied repeated-measures mixed-effects models to analyze the annual change in eGFR for the 7,482 individuals with a recorded baseline and follow-up eGFR. The median annual alteration in eGFR was -0.18 mL/min/1.73 m²/year during 6.2 years of median follow-up. The prediction of annual change in eGFR in people with dysglycemia was enhanced by adding up to 16 biomarkers to routinely measured clinical risk factors.